Risk factor
Weak & very vulnerable to price shocks
Profitability factor
Greatly undervalued vs peers
About
Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers. Specifically, the stock is 'cheap' on P/E, undervalued on EV/EBITDA, underpriced
Target Price
The average target price of BHC is 7.0 and suggests 0% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation sug
Buy
Sell